Benefit of dual bronchodilator therapy on exacerbations in former and current smokers with chronic obstructive pulmonary disease in real-world clinical practice: a multicenter validation study (TOReTO)

Abstract Background Dual bronchodilator therapy, consisting of a long-acting beta-agonist (LABA) and a long-acting muscarinic antagonist (LAMA), has proven effective for patients with chronic obstructive pulmonary disease (COPD). However, it remains uncertain whether there are efficacy differences b...

Full description

Bibliographic Details

Published in:	Respiratory Research
Main Authors:	Yu-Ting Lai, Ying-Huang Tsai, Meng-Jer Hsieh, Ning-Hung Chen, Shih-Lung Cheng, Chi-Wei Tao, Yu-Feng Wei, Yao-Kuang Wu, Ming-Cheng Chan, Shih-Feng Liu, Wu-Huei Hsu, Tsung-Ming Yang, Ching-Lung Liu, Ping-Hung Kuo, Ming-Shian Lin
Format:	Article
Language:	English
Published:	BMC 2024-10-01
Subjects:	Chronic obstructive pulmonary disease Long-acting beta-agonist (LABA)/long-acting muscarinic antagonist (LAMA) mMRC scores CAT scores FEV1 Exacerbation rates
Online Access:	https://doi.org/10.1186/s12931-024-02971-3